IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent
Qiao, Shubin1; Chen, Lianglong2; Chen, Shaoliang3; Wang, Weimin4; Zhu, Guoying5
刊名AMERICAN JOURNAL OF CARDIOLOGY
2014-02-15
DOI10.1016/j.amjcard.2013.10.042
113期:4页:613-620
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]PERCUTANEOUS CORONARY INTERVENTIONS ; ANTIPLATELET THERAPY ; TASK-FORCE ; TRIALS ; SAFETY ; DEFINITIONS ; GUIDELINES ; CARDIOLOGY ; REGISTRY ; SOCIETY
英文摘要

The RESOLUTE China Registry is a prospective, multicenter, all-corners, observational study of patients in China implanted with the Resolute zotarolimus-eluting stent (R-ZES). R-ZES was commercially available before the enrollment began. All patients suitable for R-ZES implantation according to applicable guidelines were candidates for enrollment at 30 centers and were treated per standard hospital practice. Dual antiplatelet therapy (DAFT) was prescribed for a minimum of 6 months per current European Society of Cardiology guidelines and the device instructions for use. There were 1,800 patients enrolled with a mean age of 61.3 +/- 10.9 years, 76% of patients were men, and 61% had complex disease. DAPT use was 94% at 1 year. Target lesion failure (cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization) at 1 year was 3.5% (95% confidence interval 2.7% to 4.5%). The rate of cardiac death was 0.6%, target vessel myocardial infarction 2.3%, and clinically driven target lesion revascularization 0.9%. The 1-year rate of definite or probable stent thrombosis was 0.5% (8 of 1,750); 0.4% (7 of 1,750) occurred early (0 to 30 days) and 1 event occurred late (1 to 12 months). One stent thrombosis occurred in a patient who had an interruption of DAPT within the first month; all other stent thromboses occurred while on DAFT. Outcomes did not differ significantly between monitored and unmonitored patients (difference in target lesion failure, p = 0.264). In conclusion, the RESOLUTE China Registry confirms the safety and effectiveness of R-ZES in a large real-world Chinese population. (C) 2014 The Authors. Published by Elsevier Inc. All rights reserved.

语种英语
WOS记录号WOS:000331772800007
资助机构Medtronic Inc., Shanghai, China
引用统计
被引频次:7[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/59688
专题北京大学第二临床医学院
北京大学医学部管理机构_教育处
作者单位1.Wuhan Asia Heart Hosp, Wuhan, Hubei, Peoples R China
2.Fujian Med Univ, Union Hosp, Fuzhou, Fujian, Peoples R China
3.Nanjing First Hosp, Jiangshu, Peoples R China
4.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
5.Beijing Fu Wai Hosp, Beijing, Peoples R China
推荐引用方式
GB/T 7714
Qiao, Shubin,Chen, Lianglong,Chen, Shaoliang,et al. One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent[J]. AMERICAN JOURNAL OF CARDIOLOGY,2014,113(4):613-620.
APA Qiao, Shubin,Chen, Lianglong,Chen, Shaoliang,Wang, Weimin,&Zhu, Guoying.(2014).One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent.AMERICAN JOURNAL OF CARDIOLOGY,113(4),613-620.
MLA Qiao, Shubin,et al."One-Year Outcomes from an All-Comers Chinese Population of Patients Implanted With the Resolute Zotarolimus-Eluting Stent".AMERICAN JOURNAL OF CARDIOLOGY 113.4(2014):613-620.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qiao, Shubin]的文章
[Chen, Lianglong]的文章
[Chen, Shaoliang]的文章
百度学术
百度学术中相似的文章
[Qiao, Shubin]的文章
[Chen, Lianglong]的文章
[Chen, Shaoliang]的文章
必应学术
必应学术中相似的文章
[Qiao, Shubin]的文章
[Chen, Lianglong]的文章
[Chen, Shaoliang]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。